Company intelligence / Profile preview

MTG Biotherapeutics

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

MTG-201 demonstrated selective apoptosis in cancer cells with Dickkopf-3 hypermethylation, and induced immune responses against secondary/residual tumors; Phase 1 trials in mesothelioma and prostate cancer showed promising safety/tolerability and durable disease stabilization in some patients; combination with checkpoint inhibitors is actively studied

Therapeutic areas: Oncology
Modalities: Gene therapyBiologic
Industry: Biotech

Partnerships

Momotaro-Gene Inc.Kyorin Pharmaceuticals

Beyond the preview

Go deeper on MTG Biotherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MTG Biotherapeutics.